These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 19444121

  • 1. Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?
    da Silva CM, Cruz F.
    Curr Opin Urol; 2009 Jul; 19(4):347-52. PubMed ID: 19444121
    [Abstract] [Full Text] [Related]

  • 2. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.
    Schmid DM, Roy S, Sulser T, Scheiner D.
    BJU Int; 2008 Jul 25; 102 Suppl 1():7-10. PubMed ID: 18665972
    [Abstract] [Full Text] [Related]

  • 3. The case for bladder botulinum toxin application.
    Kim DK, Thomas CA, Smith C, Chancellor MB.
    Urol Clin North Am; 2006 Nov 25; 33(4):503-10, ix. PubMed ID: 17011386
    [Abstract] [Full Text] [Related]

  • 4. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
    Smith CP, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor MB.
    Urology; 2005 Jan 25; 65(1):37-41. PubMed ID: 15667859
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
    Kuo HC.
    Urology; 2008 Nov 25; 72(5):1056-60. PubMed ID: 18533231
    [Abstract] [Full Text] [Related]

  • 6. Botulinum toxin in the treatment of OAB, BPH, and IC.
    Smith CP.
    Toxicon; 2009 Oct 25; 54(5):639-46. PubMed ID: 19268490
    [Abstract] [Full Text] [Related]

  • 7. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Giannantoni A, Mearini E, Del Zingaro M, Porena M.
    Eur Urol; 2009 Mar 25; 55(3):705-11. PubMed ID: 18814955
    [Abstract] [Full Text] [Related]

  • 8. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.
    Liu HT, Chancellor MB, Kuo HC.
    Eur Urol; 2009 Oct 25; 56(4):700-6. PubMed ID: 18472208
    [Abstract] [Full Text] [Related]

  • 9. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases.
    Do Ngoc Thanh C, Audry G, Forin V.
    J Pediatr Urol; 2009 Dec 25; 5(6):430-6. PubMed ID: 19577520
    [Abstract] [Full Text] [Related]

  • 10. Refractory neurogenic detrusor overactivity.
    Cruz F, Silva C.
    Int J Clin Pract Suppl; 2006 Dec 25; (151):22-6. PubMed ID: 17169007
    [Abstract] [Full Text] [Related]

  • 11. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity.
    Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B.
    Urology; 2006 Dec 25; 68(6):1193-7. PubMed ID: 17141831
    [Abstract] [Full Text] [Related]

  • 12. Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going.
    Sahai A, Khan MS, Gregson N, Smith K, Dasgupta P, GKT Botulinum Study Group.
    Nat Clin Pract Urol; 2007 Jul 25; 4(7):379-86. PubMed ID: 17615549
    [Abstract] [Full Text] [Related]

  • 13. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
    Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A.
    J Urol; 2009 Oct 25; 182(4):1453-7. PubMed ID: 19683298
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
    Chenet A, Perrouin-Verbe B, Le Normand L, Labat JJ, Brunel P, Lefort M, Mathé JF.
    Ann Readapt Med Phys; 2007 Nov 25; 50(8):651-60. PubMed ID: 17490775
    [Abstract] [Full Text] [Related]

  • 15. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection.
    Khan S, Kessler TM, Apostolidis A, Kalsi V, Panicker J, Roosen A, Gonzales G, Haslam C, Elneil S, Fowler CJ, Dasgupta P.
    J Urol; 2009 Apr 25; 181(4):1773-8. PubMed ID: 19233414
    [Abstract] [Full Text] [Related]

  • 16. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
    Giannantoni A, Mearini E, Del Zingaro M, Santaniello F, Porena M.
    BJU Int; 2008 Jul 25; 102 Suppl 1():2-6. PubMed ID: 18665971
    [Abstract] [Full Text] [Related]

  • 17. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.
    Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M.
    J Urol; 2004 Jul 25; 172(1):240-3. PubMed ID: 15201783
    [Abstract] [Full Text] [Related]

  • 18. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms.
    Cruz F, Dinis P.
    Neurourol Urodyn; 2007 Oct 25; 26(6 Suppl):920-7. PubMed ID: 17705161
    [Abstract] [Full Text] [Related]

  • 19. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
    Pannek J, Göcking K, Bersch U.
    BJU Int; 2009 Nov 25; 104(9):1246-50. PubMed ID: 19426192
    [Abstract] [Full Text] [Related]

  • 20. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?
    Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC.
    Neurourol Urodyn; 2005 Nov 25; 24(3):231-6. PubMed ID: 15747344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.